REDUCE-AMI Journal Club
We break down evidence-based medicine so you don't have to! This journal club will discuss the new REDUCE-AMI trial that is hot in the cardiology literature right now.
The New England Journal of Medicine published the REDUCE-AMI trial in April 2024. This post is a journal club breaking down the REDUCE-AMI trial and what change it may bring to our clinical practice.
Thanks to High Powered Medicine (@highpoweredmedicine on Instagram) for helping construct this post!
Link to the trial on NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2401479Background/Overview
Title: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction
Citation: Yndigegn T, Lindahl B, Mars K, et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024;390(15):1372-1381.
Objective: To determine the effect of long-term beta-blocker therapy on cardiovascular outcomes in patients post-myocardial infarction with preserved ejection fraction.
Primary Efficacy Measure: Composite of all-cause mortality or myocardial infarction